Related Experiment Video
Updated: Jul 1, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Glycocalyx disruption mediates HP-PRRSV-induced microvascular endothelial dysfunction and underlies astragalus
Nuohan Xia1, Jian Sun2, Ge Hu1
1Beijing Key Laboratory of Traditional Chinese Veterinary Medicine, Animal Science and Technology College, Beijing University of Agriculture, Beijing, China.
Background:
Pulmonary microvascular endothelial cells (MVECs) are not only targets of the highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) but also the pivotal hub of inflammation, interacting with alveolar macrophages to amplify the inflammatory response and determine the extent of tissue damage. Glycocalyx disruption in MVECs is often the initiating factor of numerous functional disorders, and astragalus polysaccharide (APS) has been shown to improve glycocalyx integrity in MVECs.
Aim:
This study aimed to investigate the mediating role of glycocalyx disruption in HP-PRRSV-induced pulmonary microvascular endothelial dysfunction and the glycocalyx contribution to the anti-HP-PRRSV efficacy of APS.
Methods:
In vitro porcine pulmonary MVECs were infected with the HP-PRRSV JXA1 strain and treated with APS with or without prior glycocalyx degradation mediated by heparinase (HPA) III. The expression of glycocalyx components, PRRSV N protein, and adhesion molecules was detected using western blotting or flow cytometry. The barrier function was analyzed by measuring trans-endothelial electric resistance (TEER) and permeability of horseradish peroxidase-labeled streptavidin (HRP-SA). Furthermore, neutrophil TEM and its bactericidal capacity were assayed using Transwell plates.
Results:
HP-PRRSV infection reduced the expression of heparan sulfate proteoglycan 2 (HSPG-2), glypican-1, and syndecan-1 proteoglycans. It also lowered labeled Lens culinaris agglutinin, Datura stramonium agglutinin, and Phaseolus vulgaris agglutinin-E -reactive glycan ligand levels in porcine pulmonary MVECs. However, APS significantly alleviated this damage. Furthermore, its infection decreased TEER, increased HRP-SA permeability, elevated vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression, promoted neutrophil TEM, and impaired their bactericidal activity. APS markedly suppressed HP-PRRSV replication and restored these virus-induced impairments. Conversely, enzymatic glycocalyx removal with HPA III intensified microvascular endothelial injury and largely weakened the APS's restorative effect.
Conclusion:
Glycocalyx disruption is a critical pathogenic event that orchestrates pulmonary microvascular endothelial dysfunction during HP-PRRSV infection. More importantly, we delineated a novel mechanism by which APS exerts its therapeutic effects.
Insights
Astragalus polysaccharide (APS) protects pulmonary microvascular endothelial cells (MVECs) from highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) by maintaining glycocalyx integrity. Glycocalyx disruption worsens HP-PRRSV-induced lung injury, while APS treatment restores endothelial function.
Area of Science:
- Veterinary Virology
- Cell Biology
- Immunology
Background:
- Pulmonary microvascular endothelial cells (MVECs) are key targets and inflammatory hubs during highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) infection.
- Glycocalyx disruption in MVECs initiates functional disorders, and astragalus polysaccharide (APS) is known to improve its integrity.
Purpose of the Study:
- To investigate the role of glycocalyx disruption in HP-PRRSV-induced pulmonary microvascular endothelial dysfunction.
- To determine the contribution of the glycocalyx to the therapeutic efficacy of APS against HP-PRRSV.
Main Methods:
- HP-PRRSV infection of porcine pulmonary MVECs, treated with APS with or without prior glycocalyx degradation (heparinase III).
- Analysis of glycocalyx components, viral protein, adhesion molecules, barrier function (TEER, HRP-SA permeability), and neutrophil function.
- Detection methods included western blotting, flow cytometry, and Transwell assays.
Main Results:
- HP-PRRSV infection reduced key glycocalyx components and induced endothelial dysfunction (decreased TEER, increased permeability, elevated adhesion molecules), and impaired neutrophil function.
- APS treatment alleviated HP-PRRSV-induced damage, suppressed viral replication, and restored endothelial and neutrophil functions.
- Enzymatic removal of the glycocalyx exacerbated injury and diminished APS efficacy.
Conclusions:
- Glycocalyx disruption is a critical factor in HP-PRRSV-induced pulmonary microvascular endothelial dysfunction.
- APS exerts therapeutic effects by preserving glycocalyx integrity and function, offering a novel therapeutic mechanism.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release

